

agents and antineoplastic agents  
 INVENTOR(S): Mittmann, Ulrich; Sachetto, Jean-Pierre  
 PATENT ASSIGNEE(S): Tillotts Pharma AG, Switz.  
 SOURCE: PCT Int. Appl., 33 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: **Patent**  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123061	A1	20051229	WO 2005-EP6413	20050615
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2004-13730 A 20040618  
 ED Entered STN: 30 Dec 2005

AB Polyunsatd. fatty acid ("PUFA") or a pharmacol. acceptable salt or derivative thereof (such as EPA and/or DHA) is used in combination with at least one of an immunosuppressive agent or an antineoplastic agent or a pharmacol. acceptable salt or derivative thereof in the treatment of conditions involving acutely or chronically inadequate immune response by topical application of said active agents to at least a portion of the intestinal mucosa. Specific conditions that may be treated include chronic inflammatory disease (e.g. Crohn's disease and ulcerative colitis) and tumor disease (e.g. bowel cancer and prostate cancer). One advantage of preferred embodiments of the invention is that bioavailability of immunosuppressive or antineoplastic agents is increased. For example, capsules contained fish oil (over 60% of DHA and Incromega 3F60 EPA), Eudragit NE 30D coating, polysorbate 80.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L139 ANSWER 60 OF 73 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:1355507 HCAPLUS Full-text  
 DOCUMENT NUMBER: 144:74884  
 TITLE: A pharmaceutical compositions containing polyunsaturated fatty acids in combination with immunosuppressive agents and antineoplastic agents  
 INVENTOR(S): Mittmann, Ulrich; Sachetto, Jean-Pierre  
 PATENT ASSIGNEE(S): Tillotts Pharma AG, Switz.  
 SOURCE: PCT Int. Appl., 33 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: **Patent**  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123060	A1	20051229	WO 2005-EP6412	20050615

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2004-13729 A 20040618

ED Entered STN: 30 Dec 2005

AB Polyunsatd. fatty acid ("PUFA") or a pharmacol. acceptable salt or derivative thereof (such as EPA and/or DHA) is used in combination with at least one of an immunosuppressive agent or an antineoplastic agent or a pharmacol. acceptable salt or derivative thereof in the treatment of conditions involving acutely or chronically inadequate immune response by topical application of said active agents to at least a portion of the intestinal mucosa. Specific conditions that may be treated include chronic inflammatory disease (e.g. Crohn's disease and ulcerative colitis) and tumor disease (e.g. bowel cancer and prostate cancer). One advantage of preferred embodiments of the invention is that bioavailability of immunosuppressive or antineoplastic agents is increased. For example, capsules contained fish oil (over 60% of DHA and Incromega 3F60 EPA), Eudragit NE 30D coating, polysorbate 80.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L139 ANSWER 61 OF 73 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:1223775 HCAPLUS Full-text  
 DOCUMENT NUMBER: 143:483122  
 TITLE: Methods and articles for the delivery of drugs to the eye for the treatment of posterior segment diseases  
 INVENTOR(S): Schultz, Clyde  
 PATENT ASSIGNEE(S): Directcontact LLC, USA  
 SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S. Ser. No. 971,997.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005255144	A1	20051117	US 2005-102454	20050409
US 2005208102	A1	20050922	US 2004-821718	20040409
US 2005074497	A1	20050407	US 2004-971997	20041022
PRIORITY APPLN. INFO.:			US 2003-461354P	P 20030409
			US 2004-821718	A2 20040409
			US 2004-971997	A2 20041022

ED Entered STN: 18 Nov 2005

AB This invention provides articles and methods for drug delivery including a hydrogel containing one or more drugs for the treatment of a posterior segment disease and/or dry eye conditions. Exemplary drugs are anti-angiogenesis compds. for the treatment of macular degeneration. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended

period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concns. of compds., e.g., from eye drops.

L139 ANSWER 62 OF 73 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:983601 HCAPLUS Full-text  
 DOCUMENT NUMBER: 143:272523  
 TITLE: Stable ophthalmic oil-in-water emulsions containing sodium hyaluronate for alleviating dry eye  
 INVENTOR(S): Yu, Zhi-Jian; Huth, Stanley W.; Crawford, Lauren L.; Cook, James N.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. Ser. No. 802,153.  
 CODEN: USXXCO  
 DOCUMENT TYPE: **Patent**  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005196370	A1	20050908	US 2005-98827	20050404
US 2004185068	A1	20040923	US 2003-392375	20030318
US 2004191284	A1	20040930	US 2004-802153	20040317
PRIORITY APPLN. INFO.:			US 2003-392375	A2 20030318
			US 2004-802153	A2 20040317

ED Entered STN: 09 Sep 2005

AB Stable oil-in-water emulsions are described which contain a demulcent for the treatment of dry eye such as sodium hyaluronate. The oil-in-water emulsions are stable and have anti-microbial activity sufficient for use as contact lens disinfecting solns. Thus, an emulsion contained sodium chlorite 65 and WSCP 3 ppm, sodium hyaluronate 0.1, castor oil 1.25, ethoxylated hydrogenated castor oil 1, boric acid 0.6, sodium borate decahydrate 0.035, calcium chloride dihydrate 0.006, MgCl<sub>2</sub>.6H<sub>2</sub>O 0.006, KCl 0.14, NaCl 3.5, and water qs to 100%.

L139 ANSWER 63 OF 73 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:902155 HCAPLUS Full-text  
 DOCUMENT NUMBER: 141:384286  
 TITLE: Novel encochleation methods, cochleates and methods of use  
 INVENTOR(S): Mannino, Raphael J.; Gould-Fogerite, Susan; Krause-Elsmore, Sara L.; Delmarre, David; Lu, Ruying  
 PATENT ASSIGNEE(S): Biodelivery Sciences International, Inc., USA; University of Medicine and Dentistry of New Jersey  
 SOURCE: PCT Int. Appl., 195 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: **Patent**  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091578	A2	20041028	WO 2004-US11026	20040409
WO 2004091578	C1	20050127		
WO 2004091578	A3	20050331		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005013854 A1 20050120 US 2004-822230 20040409  
 EP 1624858 A2 20060215 EP 2004-759375 20040409

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.:

US 2003-461483P P 20030409  
 US 2003-463076P P 20030415  
 US 2003-499247P P 20030828  
 US 2003-502557P P 20030911  
 US 2003-532755P P 20031224  
 US 2004-537252P P 20040115  
 US 2004-556192P P 20040324  
 WO 2004-US11026 W 20040409

ED Entered STN: 28 Oct 2004

AB The invention generally relates to cochleate drug delivery vehicles. Disclosed are novel methods for making cochleates and cochleate compns. that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compns. that include an aggregation inhibitor, and optionally, a cargo moiety. Addnl., anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a neg. charge lipid are disclosed. Methods of using the cochleate compns. of the invention, including methods of administration, are also disclosed.

L139 ANSWER 64 OF 73 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:100508 HCAPLUS Full-text

DOCUMENT NUMBER: 140:157440

TITLE: Methods for treating an autoimmune disease using a soluble CTLA4 molecule in combination with a DMARD or NSAID

INVENTOR(S): Cohen, Robert; Carr, Suzette; Hagerty, David; Peach, Robert J.; Becker, Jean-Claude

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 189 pp., Cont.-in-part of U.S. Ser. No. 898,195.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004022787	A1	20040205	US 2003-419008	20030418
US 2003083246	A1	20030501	US 2001-898195	20010702
PRIORITY APPLN. INFO.:			US 2000-215913P	P 20000703
			US 2001-898195	A2 20010702

ED Entered STN: 08 Feb 2004

AB The present invention relates to compns. and methods for treating immune system diseases such as rheumatic disease, by administering to a subject

soluble CTLA4 (cytotoxic T lymphocyte antigen 4) mols. that block endogenous B7 (CD80) mols. from binding their ligands, alone, or in conjunction with other agents including disease modifying anti-rheumatic drugs (DMARDs) or non-steroidal anti-inflammatory drugs (NSAIDs). The soluble CTLA4 mol. comprises the extracellular domain (residues 1-124) of full-length human CTLA4, which may be fused at the N-terminus with the signal peptide of oncostatin M and at the C-terminal end with an Igγ1 constant region. Single-site and double-site CTLA4 mutant sequences are also constructed, including L104E/A29Y-CTLA4/Ig, L104E/A29L-CTLA4/Ig, L104E/A29T-CTLA4/Ig, and L104E/A29W-CTLA4/Ig. CTLA4/Ig administered at 10 mg/kg (plus methotrexate) has superior efficacy in treatment of rheumatoid arthritis compared to placebo (plus methotrexate) based on efficacy parameters of the American Collage of Rheumatol. Core Data Set and Response Definitions (ACR). Binding kinetics to CD86 and CD80, pharmacokinetics, and pharmacodynamics of C-reactive protein, rheumatoid factor, interleukin-2 receptor, interleukin -6, and tumor necrosis factor α. are provided.

L139 ANSWER 65 OF 73 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:9767 HCAPLUS Full-text  
 DOCUMENT NUMBER: 136:74627  
 TITLE: Drug compositions containing cyclosporin and their application as topical systems  
 INVENTOR(S): Wohlrab, Johannes; Neubert, Reinhard; Jahn, Konstanze  
 PATENT ASSIGNEE(S): Germany  
 SOURCE: Ger. Offen., 14 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10029404	A1	20020103	DE 2000-10029404	20000615
CA 2470230	AA	20030626	CA 2001-2470230	20011214
WO 2003051385	A1	20030626	WO 2001-EP14749	20011214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002231703	A1	20030630	AU 2002-231703	20011214
EP 1455810	A1	20040915	EP 2001-991845	20011214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001017197	A	20041214	BR 2001-17197	20011214
CN 1582161	A	20050216	CN 2001-823950	20011214
US 2005106189	A1	20050519	US 2003-498656	20011214
JP 2005516931	T2	20050609	JP 2003-552318	20011214
NZ 534061	A	20060127	NZ 2001-534061	20011214
NO 2004003001	A	20040914	NO 2004-3001	20040713
PRIORITY APPLN. INFO.:			DE 2000-10029404	A 20000615
			WO 2001-EP14749	W 20011214

ED Entered STN: 04 Jan 2002

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.